Cover Image

Prevalence of Albuminuria Across Cardiovascular‐Kidney‐Metabolic Phenotypes in the United States

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Sophie E. Claudel, Donald M. Lloyd‐Jones, Sushrut S. Waikar, Ashish Verma
Format:	Artículo Open Access
Published:	Wiley 2026
Subjects:	Diabetes, Obesity and Metabolism
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prevalence of Cardiovascular‐Kidney‐Metabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (Class III ) Obesity
by: Saif S. Rathore, et al.
Published: (2026)

Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
by: Evan Zeitler, et al.
Published: (2026)

The Evolving Role of High‐Sensitivity C‐Reactive Protein for Mortality Prediction Across the Spectrum of Cardiovascular–Kidney–Metabolic Syndrome
by: Jing Li, et al.
Published: (2026)

Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular–Kidney–Metabolic Syndrome Stages 2–3
by: Xuefei Han, et al.
Published: (2026)

Diabetic kidney disease, biomarkers, and finerenone
by: Ashish Verma, et al.
Published: (2026)

Association of Physical Activity With All‐Cause and CVD Mortality Across Metabolic and Obesity Phenotypes
by: Yunmin Han, et al.
Published: (2026)

A Physiological Model of Incretin‐Based Therapies and Hierarchical Energy Allocation Across Metabolic Phenotypes
by: Christine Stier, et al.
Published: (2026)

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology
by: Michelantonio De Fano, et al.
Published: (2026)

Intrapancreatic Fat Deposition and Metabolic Signatures Across Adiposity Phenotypes in Chinese Adults: A Computed Tomography Analysis
by: Wenlu Zong, et al.
Published: (2026)

Enriched Metabolic Phenotyping Refines Phenotypic Resolution of Type 2 Diabetes
by: Min Wang, et al.
Published: (2026)

Concurrence of the Core Mechanistic Tenets of the American Heart Association Statement on the Cardiovascular–Kidney–Metabolic Syndrome and the Adipokine Hypothesis of Heart Failure With Preserved Ejection Fraction
by: Milton Packer
Published: (2026)

Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis
by: Joe Hollinghurst, et al.
Published: (2026)

Association of Cardiovascular‐Kidney‐Syndrome and Brain Macrostructure and Microstructure Injury: A Prospective Cohort Study
by: Guanyu Niu, et al.
Published: (2026)

Correction to “Association of Cardiovascular‐Kidney‐Syndrome and Brain Macrostructure and Microstructure Injury: A Prospective Cohort Study”
Published: (2026)

Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses
by: David Z. I. Cherney, et al.
Published: (2026)

Serum IGF ‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Yongin Cho, et al.
Published: (2026)

High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics
by: Srilaxmi Kalavalapalli, et al.
Published: (2026)

Sex‐Specific Associations of Inflammatory Biomarkers With All‐Cause and Cardiovascular Mortality Across Glycaemic Status: A Prospective UK Biobank Study
by: Yawen Zhang, et al.
Published: (2026)

Pathways between race, structural racism, and obesity across census tracts in the United States
by: Leonard E. Egede, et al.
Published: (2026)

The Effect of Canagliflozin Dose on Renal and Cardiovascular Outcomes in Type 2 Diabetes and High Cardiovascular Risk
by: Elias John Elenjickal, et al.
Published: (2026)

Cost‐Effectiveness of Control‐ IQ + Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States
by: Neda Al Rawashdh, et al.
Published: (2026)

Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
by: Masaru Matsui, et al.
Published: (2026)

Dose–Response Effect of Glucagon on Glucose, Beta‐Cell Secretion and Metabolism in Healthy Individuals
by: Sophie Betty Brock, et al.
Published: (2026)

Kidney Effects of Finerenone Added to Sodium‐Glucose Cotransporter 2 Inhibitors in Patients With Diabetic Kidney Disease
by: Qing Yang, et al.
Published: (2026)

Semaglutide and Cardiovascular Outcomes According to Baseline Aspirin Use: Analyses of the SOUL and SELECT Trials
by: Dirk Müller‐Wieland, et al.
Published: (2026)

The impact of overweight and obesity on health outcomes in the United States from 1990 to 2021
by: Omar Al Ta'ani, et al.
Published: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
by: Yunwen Xu, et al.
Published: (2025)

Supporting Weight Management for Kidney Transplant Candidates in People With Obesity on Haemodialysis: The First National Survey of UK Kidney Healthcare Providers
by: Adrian Brown, et al.
Published: (2026)

Disparities in heart failure deaths among people with diabetes in the United States: 1999–2020
by: Benjamin Grobman, et al.
Published: (2025)

Regional disparities in type 2 diabetes prevalence and associated risk factors in the United States
by: Sulakshan Neupane, et al.
Published: (2024)

Diabetes, Obesity and Metabolism
Published: (2026)

Diabetes, Obesity and Metabolism
Published: (2026)

Diabetes, Obesity and Metabolism
Published: (2026)

Diabetes, Obesity and Metabolism
Published: (2024)

Diabetes, Obesity and Metabolism
Published: (2024)

Diabetes, Obesity and Metabolism
Published: (2025)

Diabetes, Obesity and Metabolism
Published: (2024)

Diabetes, Obesity and Metabolism
Published: (2024)

Diabetes, Obesity and Metabolism
Published: (2024)

Diabetes, Obesity and Metabolism
Published: (2024)